help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Related articles in The Oncologist
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bilchik, A. J.
Right arrow Articles by Allegra, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bilchik, A. J.
Right arrow Articles by Allegra, D. P.
The Oncologist, Vol. 6, No. 1, 24-33, February 2001
© 2001 AlphaMed Press


DIALOGUES IN ONCOLOGY

Radiofrequency Ablation of Unresectable Hepatic Malignancies: Lessons Learned

Anton J. Bilchika,b, Thomas F. Wooda, David P. Allegrab

a Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, California, USA; b the Cancer Center at Century City Hospital, Los Angeles, California, USA

Correspondence: Anton J. Bilchik, M.D., Ph.D., F.A.C.S., John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, California 90404, USA. Telephone: 310-449-5206; Fax: 310-449-5261; e-mail: bilchika{at}jwci.org

Radiofrequency ablation (RFA) is increasingly used for the local destruction of unresectable hepatic malignancies. Relative contraindications include tumors in proximity to vital structures that may be injured by RFA and lesions whose size exceeds the ablation capabilities of the probe system employed. Given current technology, we believe that RFA should be cautiously utilized for lesions greater than 5 cm in diameter. Open (celiotomy) and laparoscopic approaches to RFA allow intraoperative ultrasonography, which may demonstrate occult hepatic disease. In addition, RFA performed via celiotomy can be accompanied by resection or cryosurgical ablation, and isolation of the liver from adjacent organs. Percutaneous RFA should be reserved for patients who cannot undergo general anesthesia, those with recurrent or progressive lesions, and those with smaller lesions sufficiently isolated from adjacent organs. Complications may be minimized when these approaches are selectively applied.

Key Words. Radiofrequency ablation • Hepatic malignancies


Related articles in The Oncologist:

Emerging New Opportunities for Patients with Hepatic Metastases from Colorectal Cancer or Primary Hepatocellular Cancer
H.M. Pinedo and C.J. van Groeningen
The Oncologist 2001 6: 12-13. [Full Text]  

Radiofrequency Ablation of Malignant Liver Tumors
Steven A. Curley
The Oncologist 2001 6: 14-23. [Abstract] [Full Text]  






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2001 by AlphaMed Press.